Nivolumab With DC Vaccines for Recurrent Brain Tumors (AVERT)
This is a trial testing
- CMV-targeted dendritic cell vaccine +
- PD-1 antibody (nivolumab)
- a single dose of Td toxoid (tetanus-diptheria) prior to the fourth vaccination
The trial is for first or second recurrence of high grade glioma (grade III or IV), no prior treatment with Avastin (bevacizumab), age 18-80.